ClinicalTrials.gg
Status unknownNCT04477057Updated Jul 20, 2020

PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-10241 in Solid Tumor, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-20.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.

Read the detailed description

This is a phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of single and multiple doses of oral administration of HS-10241 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy. There is a dose-escalation study, which is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and repeat doses of HS-10241 given once every day (QD). An alternative dosing schedule of twice every day (BID) may be investigated if the drug clearance of HS-10241 is faster than anticipated.

All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression once every 6 weeks, if the product is well tolerated and the subject has stable disease or better. As the disease progresses, survival follow-up is recommended bimonthly.

02

Conditions studied

  • Solid Tumor

Keywords

  • phase 1, solid tumor, inhibitor of c-Met kinase
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form.
  2. Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
  3. or cytologically confirmed solid tumor, either to standard therapy or for which no effective standard therapy is available.
  4. performance status of 0-1, estimated greater than (>) three months.
  5. At least 1 lesion that has not previously been irradiated, that has not been chosen for during the study screening period, and that can be accurately measured at Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), whichever is suitable for accurately repeated measurements.
  6. Females should be using adequate measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have a negative pregnancy test prior to start of dosing if of or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at Screening:

    1. defined as age more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
    2. Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.
    3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
  7. Male patients should be willing to use barrier contraception (i.e., condoms).

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    1. Any cytotoxic chemotherapy, agents, or anticancer drugs for the treatment of advanced solid tumor used for a previous treatment regimen or clinical study within 14 days of the first dose of study drug.
    2. Drugs with immunoregulatory indications within 7 days of the first dose of study drug.
    3. Medications that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.
    4. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) , unrecovered wound, ulcer, or fracture within 4 weeks of the first dose of study drug.
    5. Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study drug, with the exception of patients receiving radiation to > 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
    6. Previous or current treatment with drugs targeting the c-MET/HGF pathway.
  2. Any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of starting study treatment, with the exception of alopecia.
  3. Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 2 weeks prior to start of study treatment. Meningeal or brainstem .
  4. Pleural or peritoneal effusion requiring clinical intervention (except for effusion stable at least 1 week after clinical intervention). Pericardial effusion (except for non-tumorous micro pericardial effusions).
  5. The tumor compresses or invades important surrounding organs (such as trachea, esophagus, superior vena cava, heart, and aorta, etc), or causes significant mediastinal displacement.
  6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the investigator's opinion, makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol such as active infection (e.g., , , or [HIV]). Screening for chronic conditions is not required.
  7. Any active infection requiring treatment or systemic anti-infective agent used in one week prior to first dose administration.
  8. Active hemoptysis, active diverticulitis, peritoneal abscess, gastrointestinal obstruction that requires clinical intervention.
  9. Medical history of arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or , within 6 months prior to screening. Medical history of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months prior to screening.
  10. Varices of the esophagus or stomach that require immediate intervention (e.g., sclerotherapy).
  11. Any life-threatening bleeding events or Grade 3 or 4 gastrointestinal/varicose bleeding events requiring blood transfusion, endoscopy, or surgical treatment occurred within 3 months prior to enrollment.
  12. Hepatic encephalopathy, hepatorenal syndrome, or Grade B or more severe cirrhosis.
  13. Any of the following cardiac criteria:

    1. Resting interval (QTc) > 470 ms obtained from (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
    2. Any abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms).
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
    4. (LVEF) ≤ 40%.
    5. Any newly diagnosed clinically important arrhythmia which is no reasonable reason other than tumor to explain within 3 months prior to enrollment.
  14. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
  15. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:

    1. (ANC) \<1.5×109 / L
    2. count \<100×109 / L
    3. \<90 g/L(\<9 g/dL)
    4. (ALT) > 2.5 × (ULN) if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
    5. Aspartate aminotransferase (AST) > 2.5 × ULN if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
    6. Total (TBL) > 1.5 × ULN if no liver metastases or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    7. Serum albumin (ALB) \< 28 g/L, patients corrected by supplementation with human albumin should to exclude.
    8. Creatinine > 1.5 × ULN concurrent with \< 50 mL/min (measured or calculated by the Cockcroft-Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 × ULN.
    9. Urine protein ≥ 2+. When the Urine protein ≥ 2+ at baseline, 24-hour urine for collection, if the protein content in urine is less than 1g for 24 hours, inclusion is allowed.
  16. nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of HS-10241.
  17. History of to any active or inactive ingredient of HS-10241 or to drugs with a similar chemical structure or class to HS-10241.
  18. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  19. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
  20. History of other primary , excluding:

    1. Malignancies that have been recovered, have been inactive for ≥5 years prior to inclusion and have a very low risk of recurrence.
    2. Non-melanoma skin cancer or malignant freckle mole with adequate treatment and no evidence of disease recurrence.
    3. Carcinoma in situ with adequate treatment and no evidence of disease recurrence.
  21. Women who are breastfeeding or have a positive serum pregnancy test at Screening.
  22. Any uncontrolled metabolic dysfunction, local or systemic disease that is not caused by a malignant tumor, disease or symptoms secondary to the tumor, can lead to higher medical risk and/or uncertainty in the evaluation of survival.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    one arm

    one arm

    Drug: HS-10241

Interventions

  • HS-10241 is a tablet in the form of 100 mg, oral, once daily.

06

What researchers measure

Primary outcomes

  1. Number of subjects with any dose limiting toxicity (DLT)

    DLT is defined as one of the following HS-10241 related adverse event (AE) that occurs during the DLT period, excluding AE assessed by investigator exclusively related to subject's underlying disease or medical condition (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0): Grade 4 hematological toxicity and Grade ≥ 3 non-hematological toxicity.

    Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).

  2. To determine the maximum tolerated dose (MTD)

    MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.

    Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, RECIST1.1, and NCI CTCAE v5.0.

    Time frame: From baseline until 28 days after the last dose

  2. Observed maximum plasma concentration (Cmax) after single dose of HS-10241

    In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10241 on Day 1 to Day 6.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  3. Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10241

    At multiple-dose, Cmax ss will be obtained on Day 1 of dosing in the second 21-Day cycle of therapy.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy

  4. Time to reach maximum plasma concentration (Tmax) after single dose of HS-10241

    In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10241 on Day 1 to Day 6.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  5. Time to reach maximum plasma concentration (Tmax) after multiple dose of HS-10241

    At multiple-dose, Tmax will be obtained on Day 1 of dosing in the second 21-Day cycle of therapy.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy

  6. Apparent terminal half-life (t1/2) after single dose of HS-10241

    Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  7. Area under plasma concentration versus time curve from zero to the 24 hour sampling time (AUC0-24) after single dose of HS-10241

    Area under the plasma concentration versus time curve from time zero to the 24 hour sampling time 24 at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  8. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10241

    Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  9. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10241

    AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose

  10. To further evaluation of the anti-tumor activity of HS-10241 by assessment of objective response rate (ORR)

    Anti-tumoral efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeat 21-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.

    Time frame: 0-360day

  11. Duration of response of HS-10241

    Duration of response assessed by RECIST 1.1. Duration of response was defined as the time from when the criteria for CR or PR were first met to the occurrence of a objective disease progression (PD) or death.

    Time frame: 0-360day

  12. Time to objective response of HS-10241

    Objective response was assessed by RECIST 1.1.

    Time frame: 0-360day

  13. Disease control rate of HS-10241

    Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was defined as the percentage of patients who have a best overall response (confirmd CR, PR, or stable disease for at least 5 weeks).

    Time frame: 0-360day

  14. Deepness of response of HS-10241

    Objective response was assessed by RECIST 1.1 thereby to evaluate deepness of response. Depth of response was defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions, or progression of non-target lesions compared with baseline.

    Time frame: 0-360day

  15. Progression-free survival of HS-10241

    Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documention of objective disease progression (PD) or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.

    Time frame: 0-360day

07

Study locations

1 of 1 sites recruiting
  • Shanghai Chest Hospital
    Shanghai, Shanghai 100021, China
    Recruiting
    • shun Lu, MD · Contactshun_lu@hotmail.com · 021-22200000
    • Shenglin Ma · Principal investigator
    • Deguang Mu · Principal investigator
    • Jianhua Chen · Principal investigator
    • Xiaorong Dong · Principal investigator
    • Xiaoju Zhang · Principal investigator
    • Xingya Li · Principal investigator
    • Yubiao Guo · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2019 (actual). Primary completion is estimated for Dec 2020, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Jul 20, 2020
StartActual
Jun 21, 2019
Primary completionEst.
Dec 31, 2020
CompletionEst.
Dec 31, 2021
Last update
Jul 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04477057
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Jun 21, 2019
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Jul 20, 2020

Study contacts

Tianyu Sun
Contact
sunty@hspharm.com
13817295181
Shun Lu
principal investigator · Shanghai Chest Hospital
Shenglin Ma
principal investigator · First People's Hospital of Hangzhou
Deguang Mu
principal investigator · Zhejiang Provincial People's Hospital
Jianhua Chen
principal investigator · Hunan Cancer Hospital
Xiaorong Dong
principal investigator · Wuhan Union Hospital, China
Xiaoju Zhang
principal investigator · Henan Provincial People's Hospital
Xingya Li
principal investigator · The First Affiliated Hospital of Zhengzhou University
7Yubiao Guo
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: C-Met Inhibitor HS-10241

Start the discussion